Summary of Key Points
The first domestic biopharmaceutical targeting a key target for gout inflammation, "Fuxinqibaibai Danmao," has successfully made it to the preliminary review list for the 2026 national medical insurance catalog adjustment. This drug aims to address the issue of approximately 78,000 patients who have no available treatment options for gout. However, its inclusion in the medical insurance system still requires expert evaluation and price negotiation. Additionally, there is a lack of awareness among clinicians about the proper use of this medication, especially at the grassroots level. Fortunately, the recently released "Gout Precision Anti-Inflammation Clinical Practice Guidelines" provide guidance for its standardized application.
I. A Large Number of Gout Patients, Many of Whom Cannot Be Treated Effectively: Traditional Treatments Have Limitations
Gout is not just a simple case of joint pain; it is an inflammatory disease caused by the accumulation of urate. The number of patients with gout is increasing in China, with 177 million people suffering from hyperuricemia (second only to diabetes), and there are about 38.4 million gout patients, a trend that is becoming more prevalent among younger individuals. Traditional treatments involve the use of anti-inflammatory drugs such as colchicine and steroids. While 98.1% of patients can benefit from these drugs, the remaining 1.9% (around 78,000) face risks due to comorbidities such as cardiovascular disease, kidney disease, diabetes, or digestive issues, which may render them ineligible for these treatments. For example, people with gastric ulcers cannot use non-steroidal anti-inflammatory drugs, and those with kidney disease cannot use colchicine, leaving them in a difficult treatment situation.
II. The New Drug: A "Specialized Weapon" for Precise Targeting of Gout Inflammation
Fuxinqibaibai Danmao is the first domestic biopharmaceutical specifically designed to target the root cause of gout inflammation (IL-1β monoclonal antibody). During a gout attack, the body produces a substance called IL-1β, which acts as a "fuse" that triggers joint swelling and pain and can lead to complications. This drug directly targets this substance, controlling the inflammation at its source. Its primary target population consists of the 78,000 patients who are limited by traditional treatments. For instance, gout patients with kidney disease can use this drug without harming their kidneys while still receiving effective anti-inflammatory therapy. Phase III trials have shown that, on average, only 1.6 injections are needed over 48 weeks, making it easier for patients to adhere to the treatment regimen.
III. Medical Insurance Review is Just the First Step: Price Negotiation is Crucial
The new drug has only passed the preliminary review, which is like a "knock-on-the-door" step to enter the medical insurance catalog, checking whether the application materials meet the requirements. Two additional steps are necessary for its inclusion: expert evaluation of the drug's efficacy and safety, and price negotiation with the pharmaceutical company to determine a price that is affordable for both the insurance system and patients. As an innovative biopharmaceutical, its initial cost may be high, making price negotiation crucial. If successful, patients will be able to use the drug with medical insurance coverage, significantly reducing their financial burden; otherwise, many will still not be able to afford it. Experts also call for optimized pricing of domestically developed innovative drugs to align them with the medical insurance system and benefit more patients.
IV. Clinical Application Requires Guidance: Improving Awareness Among Clinicians, Especially at the Grassroots Level
No matter how effective a new drug is, it is useless if clinicians do not know how to use it. Currently, many doctors, especially those in grassroots hospitals, lack knowledge about this medication, including who is suitable for treatment, when to use it, and how to administer it properly. This issue can be addressed with the recently released "Gout Precision Anti-Inflammation Clinical Practice Guidelines," which provide detailed instructions on how to use IL-1β monoclonal antibodies, such as identifying patients who are restricted by traditional treatments and recommending appropriate dosages based on the severity of the condition and comorbidities. These guidelines act as a "user manual" for clinicians to ensure precise treatment.
Conclusion
The introduction of Fuxinqibaibai Danmao fills a gap in gout treatment, and passing the medical insurance review is just the first step towards making it more accessible to patients. Price negotiation and standardized clinical use are the next key milestones. The success of price negotiations will determine whether patients can afford the drug, while proper clinical application will ensure its effective use. It is hoped that this drug will be successfully included in the medical insurance system, and clinicians will quickly learn how to use it properly, ultimately benefiting the many gout patients who have no other treatment options available.